Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05102539
Other study ID # Soh-Med-21-09-08
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date October 2021
Est. completion date August 2022

Study information

Verified date October 2021
Source Sohag University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

in this study, the investigators will collect data from patients with non-invasive fungal sinusitis to know what causes it


Description:

In this study, the investigators will try to know the epidemiology of noninvasive fungal sinusitis, especially in recurrent cases This study will be carried out at sohag university hospital. Retrospective study Study period: 5 years (from August 2016 to August 2021. )


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 70
Est. completion date August 2022
Est. primary completion date August 2022
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Patients with Acute fungal sinusitis. - Patients with chronic granulomatous sinusitis. - Patients with sinus mycetomas. Exclusion Criteria: - Immunocompromised patients. - invasive fungal sinusitis.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Egypt Sohag University Hospital Sohag

Sponsors (1)

Lead Sponsor Collaborator
Sohag University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary risk factors related to non-invasive fungal sinusitis retrospective study assessed by Statistical Package for Social Sciences 5 years study period from august 2016 to august 2021
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06076304 - Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Sinusitis Phase 4
Recruiting NCT03729258 - Efficacy and Safety of Modified Release Cefpodoxime Formulation in the Treatment of Acute Sinusitis. Phase 3
Recruiting NCT05454072 - Microbiota Transfer for Chronic Rhinosinusitis N/A
Enrolling by invitation NCT05954273 - Maxillary Sinus Membrane Perforation Incidence During Osseodensification